245 related articles for article (PubMed ID: 23669347)
21. Identification of a lysosomal pathway regulating degradation of the bone morphogenetic protein receptor type II.
Durrington HJ; Upton PD; Hoer S; Boname J; Dunmore BJ; Yang J; Crilley TK; Butler LM; Blackbourn DJ; Nash GB; Lehner PJ; Morrell NW
J Biol Chem; 2010 Nov; 285(48):37641-9. PubMed ID: 20870717
[TBL] [Abstract][Full Text] [Related]
22. SEMA3G regulates BMP9 inhibition of VEGF-mediated migration and network formation in pulmonary endothelial cells.
Mirza SL; Upton PD; Hodgson J; Gräf S; Morrell NW; Dunmore BJ
Vascul Pharmacol; 2024 Jun; 155():107381. PubMed ID: 38795838
[TBL] [Abstract][Full Text] [Related]
23. Expression of mutant BMPR-II in pulmonary endothelial cells promotes apoptosis and a release of factors that stimulate proliferation of pulmonary arterial smooth muscle cells.
Yang X; Long L; Reynolds PN; Morrell NW
Pulm Circ; 2011; 1(1):103-10. PubMed ID: 22034596
[TBL] [Abstract][Full Text] [Related]
24. [Bone morphogenetic protein 4 increases canonical transient receptor potential protein expression by activating bone morphogenetic protein receptor Ⅱ/Smad signaling pathways in pulmonary arterial smooth muscle cells].
Li XY; Ran PX; Wang J
Zhonghua Jie He He Hu Xi Za Zhi; 2016 Jul; 39(7):539-45. PubMed ID: 27430926
[TBL] [Abstract][Full Text] [Related]
25. Role of bone morphogenetic protein receptors in the development of pulmonary arterial hypertension.
Morrell NW
Adv Exp Med Biol; 2010; 661():251-64. PubMed ID: 20204735
[TBL] [Abstract][Full Text] [Related]
26. Functional analysis of bone morphogenetic protein type II receptor mutations underlying primary pulmonary hypertension.
Rudarakanchana N; Flanagan JA; Chen H; Upton PD; Machado R; Patel D; Trembath RC; Morrell NW
Hum Mol Genet; 2002 Jun; 11(13):1517-25. PubMed ID: 12045205
[TBL] [Abstract][Full Text] [Related]
27. BMP type II receptor as a therapeutic target in pulmonary arterial hypertension.
Orriols M; Gomez-Puerto MC; Ten Dijke P
Cell Mol Life Sci; 2017 Aug; 74(16):2979-2995. PubMed ID: 28447104
[TBL] [Abstract][Full Text] [Related]
28. Downregulation of type II bone morphogenetic protein receptor in hypoxic pulmonary hypertension.
Takahashi H; Goto N; Kojima Y; Tsuda Y; Morio Y; Muramatsu M; Fukuchi Y
Am J Physiol Lung Cell Mol Physiol; 2006 Mar; 290(3):L450-8. PubMed ID: 16361357
[TBL] [Abstract][Full Text] [Related]
29. Correction of nonsense BMPR2 and SMAD9 mutations by ataluren in pulmonary arterial hypertension.
Drake KM; Dunmore BJ; McNelly LN; Morrell NW; Aldred MA
Am J Respir Cell Mol Biol; 2013 Sep; 49(3):403-9. PubMed ID: 23590310
[TBL] [Abstract][Full Text] [Related]
30. Altered MicroRNA processing in heritable pulmonary arterial hypertension: an important role for Smad-8.
Drake KM; Zygmunt D; Mavrakis L; Harbor P; Wang L; Comhair SA; Erzurum SC; Aldred MA
Am J Respir Crit Care Med; 2011 Dec; 184(12):1400-8. PubMed ID: 21920918
[TBL] [Abstract][Full Text] [Related]
31. CCL5 deficiency rescues pulmonary vascular dysfunction, and reverses pulmonary hypertension via caveolin-1-dependent BMPR2 activation.
Nie X; Tan J; Dai Y; Liu Y; Zou J; Sun J; Ye S; Shen C; Fan L; Chen J; Bian JS
J Mol Cell Cardiol; 2018 Mar; 116():41-56. PubMed ID: 29374556
[TBL] [Abstract][Full Text] [Related]
32. Autophagy contributes to BMP type 2 receptor degradation and development of pulmonary arterial hypertension.
Gomez-Puerto MC; van Zuijen I; Huang CJ; Szulcek R; Pan X; van Dinther MA; Kurakula K; Wiesmeijer CC; Goumans MJ; Bogaard HJ; Morrell NW; Rana AA; Ten Dijke P
J Pathol; 2019 Nov; 249(3):356-367. PubMed ID: 31257577
[TBL] [Abstract][Full Text] [Related]
33. Bone morphogenetic protein type II receptor mutations causing protein misfolding in heritable pulmonary arterial hypertension.
Li W; Dunmore BJ; Morrell NW
Proc Am Thorac Soc; 2010 Nov; 7(6):395-8. PubMed ID: 21030519
[TBL] [Abstract][Full Text] [Related]
34. Defective cellular trafficking of the bone morphogenetic protein receptor type II by mutations underlying familial pulmonary arterial hypertension.
John A; Kizhakkedath P; Al-Gazali L; Ali BR
Gene; 2015 Apr; 561(1):148-56. PubMed ID: 25688877
[TBL] [Abstract][Full Text] [Related]
35. Sex affects bone morphogenetic protein type II receptor signaling in pulmonary artery smooth muscle cells.
Mair KM; Yang XD; Long L; White K; Wallace E; Ewart MA; Docherty CK; Morrell NW; MacLean MR
Am J Respir Crit Care Med; 2015 Mar; 191(6):693-703. PubMed ID: 25608111
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of FGFR Signaling With PD173074 Ameliorates Monocrotaline-induced Pulmonary Arterial Hypertension and Rescues BMPR-II Expression.
Zheng Y; Ma H; Hu E; Huang Z; Cheng X; Xiong C
J Cardiovasc Pharmacol; 2015 Nov; 66(5):504-14. PubMed ID: 26535780
[TBL] [Abstract][Full Text] [Related]
37. Bone morphogenetic protein receptor II regulates pulmonary artery endothelial cell barrier function.
Burton VJ; Ciuclan LI; Holmes AM; Rodman DM; Walker C; Budd DC
Blood; 2011 Jan; 117(1):333-41. PubMed ID: 20724539
[TBL] [Abstract][Full Text] [Related]
38. MxA Is a Novel Regulator of Endosome-Associated Transcriptional Signaling by Bone Morphogenetic Proteins 4 and 9 (BMP4 and BMP9).
Yuan H; Sehgal PB
PLoS One; 2016; 11(11):e0166382. PubMed ID: 27875556
[TBL] [Abstract][Full Text] [Related]
39. Serotonin increases susceptibility to pulmonary hypertension in BMPR2-deficient mice.
Long L; MacLean MR; Jeffery TK; Morecroft I; Yang X; Rudarakanchana N; Southwood M; James V; Trembath RC; Morrell NW
Circ Res; 2006 Mar; 98(6):818-27. PubMed ID: 16497988
[TBL] [Abstract][Full Text] [Related]
40. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor.
Atkinson C; Stewart S; Upton PD; Machado R; Thomson JR; Trembath RC; Morrell NW
Circulation; 2002 Apr; 105(14):1672-8. PubMed ID: 11940546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
